MedTrace Logo

Study to Examine Safety, Tolerability and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight Subjects

NCT00785408 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 273

Last updated 2015-01-19

No results posted yet for this study

Summary

A randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to examine the safety, tolerability, and effect on body weight of subcutaneous AC2307 in obese or overweight subjects.

Conditions

Interventions

DRUG

AC2307

subcutaneous, twice daily, low dose

DRUG

placebo

subcutaneous, twice daily, low dose

DRUG

AC2307

subcutaneous, twice daily, middle dose

DRUG

placebo

subcutaneous, twice daily, middle dose

DRUG

AC2307

subcutaneous, twice daily, high dose

DRUG

placebo

subcutaneous, twice daily, high dose

Sponsors & Collaborators

Principal Investigators

  • Hubert Chen, MD · Amylin Pharmaceuticals, LLC.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00785408 on ClinicalTrials.gov